Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
The company targets over 50% top-line growth for FY26, driven by both regulated and emerging markets. The company targets over 50% top-line growth in FY26 compared to FY25.
From Senores Pharmaceuticals Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company targets over 50% top-line growth for FY26, driven by both regulated and emerging markets.
- Approximately 31 new ANDA product launches in the regulated market are expected in FY26.
- Around 23 CDMO-CMO products are planned for commercialization in the current financial year.
- Expansion in oral solids production capacity with two existing and two more lines being operational soon.
- Emerging market product portfolio aims to grow to over 650 registered products by FY27.
- Emerging market business margins expected to improve significantly, moving towards 15-16% EBITDA in 2 years.
- PAT guidance for FY26 is a 100% increase compared to FY25, indicating strong profitability growth.
- Growth driven by product mix changes, higher realizations, and strategic acquisitions.
- Gradual improvement in working capital metrics aims to support volume growth.
- No major capex planned; growth largely through product mix and capacity utilization.
Profitability & Margins
See what Senores Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex for FY26 is planned at INR 250 crores (Page 15).
- Oral solids capacity expansion is ongoing with the 3rd line being installed and a 4th line planned to meet increased demand (Page 9).
- New API facility (100-120 MTPA capacity) has commenced production; FDA trigger expected by Q2 2026 to support backward integration for US business (Pages 14-15).
- The API facility primarily serves in-house needs with some external sales; it is positioned strategically rather than as a separate business vertical (Pages 14-15).
- No increase in capex planned specifically for emerging markets; focus is on changing product mix to improve realization and EBITDA margins (Page 10).
- A new greenfield site for semi-regulated and regulated market support in India is planned but land finalization is pending (Page 10).
- Injectable capacity expansion planned in the US with capex scheduled by the end of the year (Page 9).
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Senores Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Senores Pharmaceuticals has a strong order book and good visibility in its CDMO-CMO segment.
- The company continues to see steady traction and scaling up in the CDMO-CMO segment.
- The portfolio now includes about 22 commercial products in CDMO-CMO with around 69 products in the pipeline at various stages.
- Many of these pipeline products are expected to be commercialized in the current fiscal year.
- The company has a solid pipeline with plans to launch 31 ANDA (Abbreviated New Drug Applications) products in the regulated market and 23 CDMO-CMO products in the current financial year.
- There are ongoing multiple discussions to utilize current capacities until the US FDA trigger is received for the API facility.
- Overall, the order pipeline and product launches provide good revenue visibility for the coming year.
Senores Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹175 Cr, net profit ₹37 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Senores Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Biocon Ltd (Q4 FY25)
FY'25 saw a consolidation and transition phase setting up for accelerated growth, with a 10% YoY increase in revenue and 16% YoY growth in core EBITDA (Page…
- Natural Capsules Ltd (Q4 FY25)
196 crore, implying about Rs. Key concall takeaways from Natural Capsules Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Laurus Labs Ltd (Q4 FY25)
Capex of around INR1,000 crore planned for FY26 primarily to expand CDMO/CMO capacities, with minimal increase in debt. Key concall takeaways from Laurus Labs…
- Wockhardt Ltd (Q4 FY25)
EBITDA growth: Recorded a 67% increase in the last year, with EBITDA margins expanding by 500 basis points from 9% to 14%. Key concall takeaways from Wockhardt…
Frequently Asked Questions
What were Senores Pharmaceuticals Ltd Q4 FY25 results?
The company targets over 50% top-line growth for FY26, driven by both regulated and emerging markets. The company targets over 50% top-line growth in FY26 compared to FY25.
What is Senores Pharmaceuticals Ltd share price analysis?
Senores Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 53.9 with a market cap of ₹6,805 Cr. Investors should review the full earnings analysis for detailed insights.
Is Senores Pharmaceuticals Ltd planning capital expenditure?
Capex for FY26 is planned at INR 250 crores (Page 15).
Keep Senores Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.